Blog and news

Article | 22.04.2021

FibroScan^® 630 Expert: Complete, Non-invasive Solution Offers Effective Management and Risk Stratification for Patients with Cirrhosis and Portal Hypertension

Webinar | 10.04.2021

Strategies For Identification of NAFLD NASH in T2DM Using Non Invasive Diagnostic Tools

Article | 10.04.2021

Type 2 diabetes: search for « fatty liver »

Article | 10.04.2021

Interest of a liver exploration for an early diagnosis of NASH

Article | 10.04.2021

FibroScan^® and the role of liver stiffness

Article | 10.04.2021

VCTE™& elastography

Webinar | 10.04.2021

Spleen Stiffness – The Noninvasive Alternative For Assessment of Portal Hypertension & Esophageal Varices Risk

Article | 09.04.2021

COVID-19 Impact: Higher Risks of Severity Among Obese and Chronic Liver Disease Patients

Article | 09.04.2021

FibroScan^® Recommended for Hepatitis C Patients

Article | 09.04.2021

Echosens Observes National Drug and Alcohol Facts Week 2021

Article | 09.04.2021

Economic Analysis Model Suggests Screening People for Fibrosis With Non-Invasive Tests Cost-effective

Press Release | 09.04.2021

International NASH Day 2020

Article | 09.04.2021

Innovative FAST™ Score Helps Clinicians Address the Epidemic of Active Fibrotic NASH

Article | 09.04.2021

Echosens Takes a Proactive Leadership Position

Article | 09.04.2021

HCV Treatments Can Cure Viral Infection, Not Neccessarily Liver Disease